Valuation: Tsubota Laboratory Incorporated

Market Cap 6.29B 38.45M 33.77M 31.4M 28.82M 54.15M 3.7B 54.98M 373M 146M 1.82B 144M 141M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.39B 32.94M 28.93M 26.91M 24.69M 46.39M 3.17B 47.11M 320M 125M 1.56B 124M 121M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
06-17 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
06-01 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/05/25 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/02/25 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/11/24 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/12/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/09/22 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
23/06/22 Tsubota Laboratory Incorporated has completed an IPO in the amount of Ñ1.8048 billion. CI
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 38.45M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.20%+0.83%+54.97%+107.37% 27.25B
Weighted average by Cap. +0.48%+0.91%+75.32%+136.64%

Financials

2025 2026
Net sales 1.36B 8.29M 7.28M 6.77M 6.21M 11.67M 798M 11.85M 80.4M 31.41M 392M 31.12M 30.45M 200M 1.22M 1.07M 998K 916K 1.72M 118M 1.75M 11.85M 4.63M 57.84M 4.59M 4.49M
Net income 205M 1.25M 1.1M 1.02M 939K 1.76M 121M 1.79M 12.15M 4.75M 59.29M 4.7M 4.6M -761M -4.65M -4.08M -3.8M -3.48M -6.55M -448M -6.65M -45.09M -17.62M -220M -17.45M -17.08M
Net Debt -1.45B -8.85M -7.77M -7.23M -6.63M -12.46M -852M -12.65M -85.8M -33.52M -419M -33.21M -32.49M -901M -5.5M -4.83M -4.5M -4.13M -7.75M -530M -7.87M -53.39M -20.86M -261M -20.66M -20.22M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
22